Method Background Result Conclusion

Slides:



Advertisements
Similar presentations
Blood pressure control in children following kidney transplantation in the UK Manish Sinha Evelina Childrens Hospital London UKRR and NHS Kidney Care Audit.
Advertisements

Terasaki Festschrift 2014 Clinical Relevance of Pre- and Post-Transplant HLA antibodies, Donor-Specific and Non-Donor-Specific HLA Antibodies Detected.
PRA = 36% (21/58) Anti-A11 and B44.
Dialysis vs Transplant: the Australia & New Zealand experience Stephen McDonald ANZDATA Registry Adelaide, South Australia.
UK Renal Registry 17th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2013.
Allocation of deceased donor kidneys Phil Clayton NSW Renal Group 14 June 2012.
Monitoring HLA-specific antibodies
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
UK Renal Registry 14th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2010.
1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.
Why don’t indigenous dialysis patients receive transplants – waitlist or allocation? N. Khanal 1, P. Clayton 1, S. McDonald 1, M. Jose 2 1 The University.
TRANSPLANTATION CHAPTER 8 ANZDATA Registry Annual Report 2013.
Single HLA Antigen Bead Data Interpretation: Normalized Ratios Peter Stastny Transplantation Immunology Division Departments of Internal Medicine and Pathology.
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
Aetiology of preoperative anaemia in patients undergoing elective cardiac surgery Jacob Abhrahm 1,Romi Sinha 2,Kathryn Robinson 3, David Cardone 1 1 Department.
Donor Matching of Kidney Transplantation
Kidney Graft Survival Rates do not improve by era: the impact of factor “Age” E. Bertoni MD, A. Larti MD, G. Rosso MD and M. Salvadori MD Renal Unit –
Obesity in the end stage kidney disease population
2 Renal Unit, Belfast City Hospital, Belfast, BT9 7AB
ASSOCIATION OF SOCIO-ECONOMIC POSITION WITH TECHNIQUE FAILURE AND MORTALITY IN AUSTRALIAN NON-INDIGENOUS PERITONEAL DIALYSIS PATIENTS Dr Samuel Chan Nephrology.
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Prevalence (pmp) of Renal Replacement Therapy
UK Renal Registry 10th Annual Report 2007
Hong Kong Workshop Lecture 8 HLA Epitopes and Acceptable Mismatches for Sensitized Transplant Patients.
ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.
Anand Yuvaraj International Transplant Fellow
CASE PRESENTATION DR SANJAY MAITRA, DR DENISH SAVALIA,
UK Renal Registry 15th Annual Report
2015 Kidney Allocation Task Force HLA Working Group
Number of transplants, by donor type figure 8.1
Relationship between Mixed Chimerism and Clinical Tolerance after Combined Kidney and Hematopoietic Cell Transplantation using Total Lymphoid Irradiation.
Single Antigen Beat Assay (Luminex) Allows Detection of Immunised Patients with an Increased Risk for Long Term Graft Survival Prior to Transplantation.
UK Renal Registry 16th Annual Report
Volume 60, Issue 1, Pages (July 2001)
UK Renal Registry 18th Annual Report
Number of Grafts Performed by Country
Clinical outcome after SVR: Veterans Affairs
Complication Rates for Percutaneous Coronary Intervention in South Australia Aashray Gupta1, Rosanna Tavella1,2, Margaret Arstall1,3, Matthew Worthley1,2,
Menachem M Meller,MD, PhD
Kidney allocation to highly sensitized patients
Paediatric Renal Transplantation
Interesting Case Conference
Volume 82, Issue 5, Pages (September 2012)
ANZDATA Registry Annual Report 2013
Towards epitope matching in kidney allocation
UK Renal Registry 13th Annual Report
Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease  Florent Delbos, Walid Barhoumi, Ludovic Cabanne,
Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at.
UK Renal Registry 16th Annual Report
Stephen P. McDonald  Kidney International Supplements 
Volume 85, Issue 2, Pages (January 2014)
Red Cell Antibodies in Healthy Blood Donors
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
K+ and K- red cells; when is it safe to transfuse?
Volume 60, Issue 1, Pages (July 2001)
Does rituximab help in HLA desensitization for kidney transplantation?
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Stephen P. Mcdonald, Graeme R. Russ  Kidney International 
Volume 71, Issue 12, Pages (June 2007)
UK Renal Registry 10th Annual Report 2007
Deceased solid organ donors Recent trends from ANZOD
Survival of End Stage Renal Failure Patients with Cancer
UK Renal Registry 9th Annual Report 2006
Prevalent Dialysis and Transplants Australia (at 31st December) Number of Patients
ANZDATA: Vascular Access
CHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES
Stock and Flow of Haemodialysis Patients Australia
Australia and New Zealand
Australia and New Zealand
Presentation transcript:

Method Background Result Conclusion Peri-Transplant Blood Transfusion Is Associated With Significant Formation of HLA Antibodies Despite Immunosuppression 1Central Northern Adelaide Renal & Transplantation Service, Royal Adelaide Hospital, Adelaide SA 5000, Australia 2 Australia and New Zealand Dialysis and Transplantation Registry, Royal Adelaide Hospital, Adelaide SA 5000, Australia 3 National Transplantation Services Australian Red Cros4 Discipline of Medicine, University of Adelaide, 5Transfusion Service Royal Adelaide Hospital, Frome Road, Adelaide SA 5000 6Centre for Stem Cell Research, University of Adelaide, Frome Road, Adelaide SA 5000, Australia Ubaidullah S.Dawood1, William Hanf1, Blair Grace2,4, Chris J. Drogemuller1,6, Greg D. Bennett3, Robert P. Carroll1, 3, 4,6, Stephen P. McDonald1, 2, 4,6, Sophia Hague5, P. Toby H. Coates1, 3, 4, 6,* Background Result Blood transfusion in kidney transplantation is considered a major risk for sensitisation. We studied the prevalence of transfusion during the transplantation period and analysed the impact on HLA antibody status. 187 patients underwent kidney transplantation during the study period (2010-13).Haemoglobin at the time of surgery were 120g/L (range 120-164) in non-transfused cohort and 116g/L (range 87-155) among the transfused cohort. 67 (36%) received blood transfusion during peri-transplantation period [mean of 2 units (range 2-14)].Mean recipient age of transfused patient was 51 +/- 12 years (36M/53F). Prior to transplantation 40/67 recipients had non-donor specific HLA antibodies and 9/67 had pre-existing DSA. We observed the formation of de novo HLA antibodies (MFI >300) in 18/67 (26%) patients with 8 HLA Class I, 5 HLA class II and 5 for both classes. The HLA antibody specificity for class I Ab was HLA B (n=11) and the HLA class II Ab was DR (n=7). We also found 4 de novo Cw locus Ab and 1 DP Ab. 5 patients developed de novo DSA after transplantation. Method We retrospectively analysed all adult kidney recipients from a single centre transfused with red blood cells and platelets during the first 48 hours of transplantation surgery. HLA tissue typing was performed by single antigen Luminex bead assay (Tepnel). HLA antibodies and donor specific antibodies (DSA) pre and post-transplantation between days 14 and 31 were analysed. All patients received prednisolone, tacrolimus and MMF. Conclusion 1) High prevalence of transfusion in peri- transplantation period (36%) 2) 26% of transfused kidney transplant recipient developed clinically significant HLA antibodies (MFI>300). 3) High prevalence of transfusion and sensitization in young patients may potentially impact future transplantation. 4)Second graft, female patient, AKPKD and non Caucasian race has higher likelihood of developing de novo HLA antibodies in our study as demonstrated in forest plot (fig1 and 2) Fig 1 Fig 2